ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
71.96
1.42%
US Dollar vs AUD
1.44829
-0.18%
Bitcoin
65,832.32
1.00%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. IDEAYA Biosciences Inc (IDYA)

  7. IDEAYA Biosciences Inc (IDYA) News

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IDYA
DateTimeSourceHeadlineSymbolCompany
28/09/202406:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
28/09/202406:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
27/09/202420:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
23/09/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
23/09/202420:00PR Newswire (US)IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
22/09/202423:00PR Newswire (US)IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
18/09/202420:00PR Newswire (US)IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General CounselNASDAQ:IDYAIDEAYA Biosciences Inc
30/08/202420:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
27/08/202407:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
26/08/202420:00PR Newswire (US)IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:IDYAIDEAYA Biosciences Inc
23/08/202420:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
07/08/202407:08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
07/08/202406:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202420:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202420:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
01/08/202409:56Business Wire百奧賽圖宣布與IDEAYA Biosciences就具有同類首創潛力的B7H3/PTK7拓撲異構酶抑制劑有效負載雙特異性ADC專案達成選擇權和授權合約NASDAQ:IDYAIDEAYA Biosciences Inc
31/07/202420:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
31/07/202420:00Business WireBiocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC ProgramNASDAQ:IDYAIDEAYA Biosciences Inc
31/07/202420:00PR Newswire (US)IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with BiocytogenNASDAQ:IDYAIDEAYA Biosciences Inc
31/07/202420:00Business WireBiocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC ProgramNASDAQ:IDYAIDEAYA Biosciences Inc
31/07/202420:00Business Wire百奥赛图宣布与IDEAYA Biosciences就具有同类首创潜力的B7H3/PTK7拓扑异构酶抑制剂有效载荷双特异性ADC项目达成选择权和许可协议NASDAQ:IDYAIDEAYA Biosciences Inc
29/07/202420:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
12/07/202406:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
12/07/202406:05PR Newswire (US)IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:IDYAIDEAYA Biosciences Inc
11/07/202407:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IDYAIDEAYA Biosciences Inc
10/07/202412:26PR Newswire (US)IDEAYA Announces Pricing of Public OfferingNASDAQ:IDYAIDEAYA Biosciences Inc
10/07/202407:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IDYAIDEAYA Biosciences Inc
10/07/202406:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
10/07/202406:08PR Newswire (US)IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:IDYAIDEAYA Biosciences Inc
08/07/202420:37IH Market NewsParamount-Skydance $28B Merger, Boeing Agrees to Plead Guilty with $243.6M Fine, and More NewsNASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA

Your Recent History

USOTC
PEBA
Penn Bancshares (CE)
NASDAQ
CORZW
Core Scientific
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved